Aclaris Therapeutics shares fall 7.91% following Phase 2 clinical trial failure for atopic dermatitis
ACRS Aclaris Therapeutics Inc
$3.38 -6.24%
View chart & analysis → - 1Aclaris Therapeutics' bosakitug failed to meet primary and secondary endpoints in the ADMIRATION Phase 2 clinical trial for atopic dermatitis.
- 2CEO Neil Walker stated that these results will not change development priorities focusing on oral kinase inhibitors and the bispecific antibody ATI-052.
- 3The AD market value across 7 major markets is projected to grow from $8.5 billion in 2023 to $21.5 billion by 2033.
So what's the key point?
Aclaris Therapeutics' bosakitug failed to meet primary and secondary endpoints in the ADMIRATION Phase 2 clinical trial for atopic dermatitis.
Source Nasdaq +2 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.